Letter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancer
World Journal of Clinical Oncology · 24.07.2026 · 17 (7)
DOI: 10.5306/wjco.120955 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Clinical Oncology, online erschienen am 24.07.2026. Verfasst von Ilya Klabukov und 3 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
We read with great interest the clinical study published in the World Journal of Clinical Oncology by Depar et al investigated the associations of cancer stem cells (CSC) markers (CD44, CD24, ALDH1) with chemotherapy response and survival in triple-negative breast cancer (TNBC) patients. Current advanced approaches for the treatment of chemoresistant TNBC focus on mRNA-based therapy as a form of personalized medicine designed to overcome conventional therapeutic resistance. Among the clinical findings, the study by Depar et al also focuses on the availability of personalized medicine alternatives for patients with hard-to-cure cancers, using Pakistan as an example of a developing economy. Beyond the other findings of the study, one particular idea is worth noting: Advanced diagnostics are needed not to replace current approaches, but to be applied in low-income economies that cannot afford high-cost diagnostic methods. Indeed, the development of expensive therapies for resistant cancers has been limited in effectiveness by population-specific genetic patterns. Screening studies aimed at identifying substitute biomarkers associated with the CSC microenvironment or tumor extracellular matrix properties could provide a basis for selecting personalized therapies. This "leapfrogging" approach appears to be especially beneficial for high-risk patients with chemoresistant TNBC.
Zitieren
APA
Klabukov, I., Baranovskii, D., Eygel, D., & Yatsenko, E. (2026). Letter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancer. World Journal of Clinical Oncology, 17(7). https://doi.org/10.5306/wjco.120955
Vancouver
Klabukov I, Baranovskii D, Eygel D, Yatsenko E. Letter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancer. World Journal of Clinical Oncology. 2026;17(7). doi:10.5306/wjco.120955
BibTeX
@article{Klabukov2026,
author = {Klabukov, Ilya and Baranovskii, Denis and Eygel, Daria and Yatsenko, Elena},
title = {Letter to the Editor: Cancer stem cell and oncomatrix biomarkers predict chemotherapy response and survival in triple-negative breast cancer},
journal = {World Journal of Clinical Oncology},
year = {2026},
volume = {17},
number = {7},
doi = {10.5306/wjco.120955}
}
EUVIMED